Arvinas Inc
ARVN13.480USD
+0.520+4.01%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
954.38MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Arvinas Inc Unternehmen
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Arvinas Inc Informationen
BörsenkürzelARVN
Name des UnternehmensArvinas Inc
IPO-datumSep 27, 2018
CEODr. John G. Houston, Ph.D.
Anzahl der mitarbeiter430
WertpapierartOrdinary Share
GeschäftsjahresendeSep 27
Addresse5 Science Park
StadtNEW HAVEN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl06511-1966
Telefon12035351456
Websitehttps://www.arvinas.com/
BörsenkürzelARVN
IPO-datumSep 27, 2018
CEODr. John G. Houston, Ph.D.
Führungskräfte von Arvinas Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Feb 5
Aktualisiert: Thu, Feb 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Andere
66.13%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.23%
BlackRock Institutional Trust Company, N.A.
8.05%
Pfizer Inc
5.38%
D. E. Shaw & Co., L.P.
5.30%
Logos Global Management LP
3.89%
Andere
66.13%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.71%
Hedge Fund
26.23%
Investment Advisor/Hedge Fund
21.31%
Venture Capital
6.56%
Corporation
5.38%
Research Firm
4.23%
Individual Investor
2.59%
Pension Fund
0.53%
Bank and Trust
0.31%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
513
61.93M
168.36%
-2.99M
2025Q3
525
64.92M
150.53%
-4.18M
2025Q2
518
67.55M
122.76%
+4.71M
2025Q1
504
63.19M
117.99%
-22.92M
2024Q4
484
75.18M
115.79%
+228.04K
2024Q3
476
75.20M
114.63%
+1.35M
2024Q2
469
73.21M
109.58%
+2.16M
2024Q1
476
70.86M
103.71%
+13.21K
2023Q4
483
66.87M
80.36%
+15.93M
2023Q3
458
50.77M
99.64%
+2.00M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
8.55M
13.31%
-831.93K
-8.87%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.17M
8.05%
-87.00K
-1.65%
Sep 30, 2025
Pfizer Inc
3.46M
5.38%
--
--
Sep 30, 2025
D. E. Shaw & Co., L.P.
3.41M
5.3%
+57.86K
+1.73%
Nov 06, 2025
Logos Global Management LP
2.50M
3.89%
-3.08M
-55.16%
Oct 14, 2025
Millennium Management LLC
2.13M
3.32%
+233.48K
+12.30%
Sep 30, 2025
State Street Investment Management (US)
1.87M
2.92%
+140.76K
+8.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.67M
2.6%
+85.09K
+5.37%
Sep 30, 2025
TCG Crossover Management, LLC
1.62M
2.52%
+1.62M
--
Sep 30, 2025
New Leaf Venture Partners LLC
1.59M
2.47%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.76%
State Street SPDR S&P Pharmaceuticals ETF
1.65%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares U.S. Pharmaceuticals ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.24%
Zacks Small/Mid Cap ETF
0.22%
iShares Health Innovation Active ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.1%
Mehr Anzeigen
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.76%
State Street SPDR S&P Pharmaceuticals ETF
Anteil1.65%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.91%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.7%
iShares U.S. Pharmaceuticals ETF
Anteil0.28%
Federated Hermes MDT Small Cap Core ETF
Anteil0.24%
Zacks Small/Mid Cap ETF
Anteil0.22%
iShares Health Innovation Active ETF
Anteil0.16%
ProShares Ultra Nasdaq Biotechnology
Anteil0.11%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.1%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
